Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450340 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL1893665 | 0.82 | HPGD (0.41) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL6326192 | 0.82 | HPGD (0.41) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL6340582 | 0.82 | SMN1; SMN2 (0.35) | ALDH1A1HPGDMAPK1SMN1; SMN2KDM4E | |
| SCHEMBL1206852 | 0.80 | KMT2A (0.38) | ALDH1A1SMN1; SMN2KDM4ELMNAKMT2A | |
| SCHEMBL441463 | 0.80 | MAPK1 (0.33) | ALDH1A1MAPK1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL7246452 | 0.80 | SMN1; SMN2 (0.36) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL27339754 | 0.80 | ALDH1A1 (0.32) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL443893 | 0.80 | CES2 (0.35) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL7355446 | 0.79 | HTT (0.46) | ALDH1A1HPGDMAPK1CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532967-B2 | Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis | LIU JUNYI (CN) | 2017-01-03 | — | — | US | claimed |
| EP-2687211-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | Liu, Junyi (CN) | 2014-01-22 | — | — | EP | claimed |
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | LIU JUNYI (CN) | 2013-11-14 | — | — | US | claimed |
| CN-102198125-A | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | JUNYI LIU | 2011-09-28 | — | — | CN | claimed |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | AMGEN, INC. (US) | 2006-10-26 | — | — | US | claimed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | claimed |
| US-9532967-B2 | Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis | LIU JUNYI (CN) | 2017-01-03 | — | — | US | disclosed |
| EP-2687211-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | Liu, Junyi (CN) | 2014-01-22 | — | — | EP | disclosed |
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | LIU JUNYI (CN) | 2013-11-14 | — | — | US | disclosed |
| CN-102198125-B | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | NANJING AIPIKA BIOTECHNOLOGY CO LTD | 2013-02-20 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-102198125-A | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | JUNYI LIU | 2011-09-28 | — | — | CN | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-4619932-A | CENTRAL NERVOUS SYSTEM CONTROLLERS; ANTI-SCHIZOPHRENIA AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-28 | — | — | US | disclosed |
| US-4567187-A | CENTRAL NERVOUS SYSTEM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-28 | — | — | US | disclosed |
| US-4460593-A | Carbostyril derivatives, and central nervous system controlling agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4455422-A | ANTIHISTAMINES, CNS CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | NR4A3, CBR3, NCOA3 | ALDH1A1 1484/4885HPGD 3065/4885MAPK1 2014/4885 |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | ALDH1A1 481/4885HPGD 31/4885MAPK1 694/4885 |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | ALDH1A1 490/4885HPGD 39/4885MAPK1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.